127
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis

, , , , , , & ORCID Icon show all
Pages 931-942 | Received 09 Jun 2020, Accepted 19 Aug 2020, Published online: 03 Oct 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

N Farina, C Campochiaro, A Lescoat, G Benanti, G De Luca, D Khanna, L Dagna & M Matucci-Cerinic. (2023) Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis. Expert Review of Clinical Immunology 19:9, pages 1131-1142.
Read now

Articles from other publishers (3)

Y. Allanore. (2022) Esclerodermia sistémica: tratamiento. EMC - Aparato Locomotor 55:4, pages 1-11.
Crossref
Lazaros I. Sakkas & Dimitrios P. Bogdanos. (2022) The Role of T Cells in Systemic Sclerosis: An Update. Immuno 2:3, pages 534-547.
Crossref
Francesco Reggiani, Gabriella Moroni & Claudio Ponticelli. (2022) Kidney Involvement in Systemic Sclerosis. Journal of Personalized Medicine 12:7, pages 1123.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.